$20m-$39.9m

Inserm Transfer Initiative featured in the first round for VectivBio, a short bowel syndrome treatment developer spun out of Therachon following the latter's acquisition by Pfizer.

Paris Descartes University's gene therapy developer has raised $42.1m altogether following a series B featuring existing investors including Inserm Transfert Initiative.

The University of Oxford DNA processing spinout tapped a consortium of unnamed investors in a round which also includes $106m in secondary funding.

Bic Camera, Brother Industries, Hi-Lex, Nac, TIS, Tokai and Towa were among the backers that supplied $32.3m for TUS spinout Innophys' series C funding.

Caltech-founded ChromaCode has now raised $42.6m in all for its molecular diagnostics technology business.

UC Berkeley-founded Anyscale has come out of stealth with the backing of investors including House Fund, Ant Financial and Intel Capital.

Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.